Pfizer Inc. and BioNTech announced that BioNTech Europe has entered an agreement with Turkey’s Ministry of Health to supply 60 million additional doses of the companies’ COVID-19 vaccine, with an option for an additional 30 million doses.
On December 25, 2020, the two companies announced an initial agreement to provide 30 million doses of the Pfizer-BioNTech vaccine to Turkey. This second supply agreement brings the total number of doses to be supplied to Turkey to up to 120 million, all of which will be delivered in 2021.
“Our goal is to deliver as many doses of our COVID-19 vaccine as possible to people around the world to help end this pandemic, reduce COVID-19-related hospitalizations and return to a normal life. We are grateful to be able to make an important contribution to Turkey's vaccination efforts and for the trust placed in us,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.
“We are hopeful that this agreement will further boost Turkey’s COVID-19 vaccination drive. Pfizer is committed to contributing to public health in Turkey and very proud to have a global partner such as BioNTech in the global fight against the pandemic,” said M. Cem Açık, Pfizer Country Manager Turkey.
The vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!